L eber hereditary optic neuropathy (LHON; OMIM #535000) is a mitochondrial genetic disease that causes blindness in young adults, with an estimated minimum prevalence of 3.2 per 100 000 in the north east of England. 1 It classically presents as bilateral subacute loss of central vision due to the focal neurodegeneration of the retinal ganglion cell layer. Over 95% of cases are principally due to one of three ''primary'' mtDNA point mutations: 3460GRA, 11778GRA, and 14484TRC, all of which involve genes that encode complex I subunits of the mitochondrial respiratory chain. However, less than ,50% of male and ,10% of female LHON carriers will develop the optic neuropathy. 2 3 This marked incomplete penetrance and gender bias clearly indicates that additional genetic and/or environmental factors are required for the phenotypic expression of the pathogenic mtDNA mutations in LHON. However, these secondary factors remain poorly defined at the present time.
There has recently been considerable interest in the possible role of the mtDNA background on the phenotypic expression of mitochondrial genetic disorders. The hypothesis is that on their own, some polymorphisms are selectively ''neutral'' but that in specific combinations, they act in a synergistic, deleterious manner with established pathogenic mtDNA mutations to increase the risk of disease expression or to produce a more severe clinical outcome. 4 The following nucleotide substitutions are found at a higher frequency in LHON patients relative to controls: [5] [6] [7] 4216TRC, 4917ARG, 9804GRA, 9438GRA, 13708GRA, 15257GRA, and 15812GRA. Phylogenetic analysis has shown that 4216TRC, 13708GRA, 15257GRA, and 15812GRA all cluster on a specific mtDNA background, haplogroup J, which is one of the nine haplogroups that define populations of European ancestry. 8 9 Several studies have subsequently found that LHON pedigrees that harbour the 11778GRA and 14484TRC mutations are apparently not randomly distributed along the phylogenetic tree, but tend to show a preferential association with haplogroup J (table 1) . It has therefore been argued that these polymorphic variants interact with the primary mtDNA mutations, increasing the risk of visual loss among LHON carriers. However, the potential pathogenic role of these so-called ''secondary'' mtDNA mutations in LHON is still controversial. All the association studies published so far involved a relatively small number of pedigrees collected over a wide geographical area by centres with a specialist interest in LHON, thereby raising the possibility of ascertainment bias. To investigate further the presumed association between primary LHON mutations and haplogroup J, we determined the haplogroup distribution of a rigorously defined, population based LHON cohort from the north east of England, and carried out a systematic statistical review of the literature. (table 2) .
MATERIALS AND METHODS

Study population
Haplogroup determination
One member of each pedigree was analysed and the haplogroup was determined by restriction enzyme analysis of the relevant PCR amplified mtDNA fragment, as described previously. 10 The haplogroup distribution of 179 normal N The most compelling explanation is that the risk of visual loss in LHON carriers with the 11778GRA and 14484TRC mutations is increased by haplogroup J, and by extension, one or more of the mtDNA polymorphisms that define this haplogroup.
controls from the north east of England had also been determined previously using the same protocol.
11
Systematic review Published studies that had analysed haplogroup distribution in LHON pedigrees were identified by searching the main electronic databases (MedLine and Web of Science) from 1988, when the first LHON mutation was reported. 12 The keywords used in the search strategy were ''optic atrophy'', ''mitochondrial DNA'', ''haplogroup'', and ''phylogeny''. The reference lists of relevant papers were also assessed for the presence of additional studies not listed in these databases. Finally, the main investigators in the field of mitochondrial genetics were also contacted personally to obtain any unpublished data that might clarify some of their published results, especially if the raw data were not provided in the original paper.
Study selection
For the purpose of this review, studies (published or unpublished) were included only if sufficient data had been collected by the investigators to allow the haplogroup to be clearly deduced for their LHON pedigrees. In some of these studies, haplogroup status was not reported directly. However, pedigrees could still be grouped as being either J or non-J, as long as the polymorphic status at nucleotide positions 4216 and 13708 had been determined. 9 10 As far as possible, we tried to ascertain that all included pedigrees were unrelated and of European extraction.
Statistical analysis
A meta-analysis was carried out using the Mantel-Haenszel method as implemented in the Cochrane Review Manager TM software (version 4.1). A fixed effect model was adopted given the lack of significant heterogeneity between the included studies (http://www.cochrane.de/cochrane/hbook.htm).
RESULTS
In our population based LHON cohort from the north east of England, there was a trend towards haplogroup J being overrepresented in 11778GRA and 14484TRC pedigrees compared with our control population, but this was not statistically significant because of the small number of pedigrees involved (table 2) . A total of 10 other haplogroup J association studies were identified through our search strategy (table 1). The main findings of our statisical metaanalysis are summarised graphically by a forest plot (fig 1) .
For the 3460GRA pedigrees, the prevalence of haplogroup J (7.8%) was not significantly different to that in normal controls (9.3%) (odds ratio (OR) = 1.29 (95% CI 0.57 to 2.90)). Haplogroup J was moderately over-represented for the 11778GRA pedigrees (26.8% v only 9.3% in controls; OR = 3.48; 95% CI 2.36 to 5.15). There was a strong association between the 14484TRC mutation and haplogroup J (OR = 27.53; 95% CI, 14.53 to 52.13). Over 75% of the 14484TRC LHON pedigrees belong to haplogroup J, as against only ,11% of the control mtDNAs.
DISCUSSION
This meta-analysis confirms the reported association between two of the primary LHON mutations, 11778GRA and 14484TRC, and haplogroup J. This was particularly marked for 14484TRC, with pedigrees harbouring this mutation being ,30 times more likely to belong to this particular haplogroup than controls. While it is important to consider the possibility that these results are influenced by the method of ascertainment, particularly through a publication bias following the identification of the so-called ''secondary'' LHON mtDNA mutations in 1991, the magnitude of the association is so great that it seems unlikely that this can be the sole explanation. Moreover, our epidemiological study of LHON in a defined geographical region revealed the same trend towards a haplogroup J association, adding weight to our conclusion.
How can we explain the association between mtDNA haplogroup J and the 11778GRA and 14484TRC mutations? It is conceivable that this could be due to an early founder effect, whereby the 11778GRA and 14484TRC mutations arose early in the evolution of haplogroup J, leading to its over-representation on that mitochondrial lineage. There is some evidence in support of this hypothesis in the Dutch population, 13 but this cannot provide a complete explanation because all three primary LHON mutations have arisen multiple times on different mitochondrial backgrounds 10 (see also the discussion in Howell et al 13 and Brown et al 14 ) . Moreover, none of these mtDNA mutations has been found in the large sample of normal control mitochondrial genomes that belong to haplogroup J (for examples, see http:// www.genpat.uu.se/mtDB/index.html). There are a number of other possible explanations for this haplogroup J association. This particular mtDNA haplogroup J appears to be associated with successful ageing, 15 a high complex I activity in spermatozoa, 16 and a lower risk of developing Parkinson's disease, 17 although the latter is still contentious. 18 These putative ''protective'' effects of haplogroup J could confer a competitive advantage, leading to persistence of LHON mutations in the population, as has already been suggested, 19 but it is difficult to see why this should be specific for the 11778GRA and 14484TRC LHON mutations only. Although a point of great debate, the most compelling 1991  175  16  159  9  2  7  ------26   1992  179  25  174  3  0  3  14  7  7  5  3  2   27   1993  175  16  159  ------15  12  3   22   1994  160  16  144  8  0  8  16  2  14  9  8  1   8   1995  175  16  159  10  1  9  17  4  13  8  6  2   28   1997  67  5  62  4  1  3  23  10  13  21  14  7   10   1997  99  7  92  7  0  7  28  11  17  2  2  0   29   1997  529  33  496  3  0  3  13  4  9  ---30   1999  78  9  69  2  0  2  27  4  23  2  1  1  Current study  179  25  174  5  0  5  9  3  6  1  1  0 In most of these studies, haplogroup distribution for a representative sample of normal controls from the local population was also reported. If the latter was not provided, this was sought either directly from the original investigators or from other published sources: Finland 9 25 and the Netherlands (Dr G Barbujani, personal communication). explanation is that the risk of visual loss is increased by haplogroup J.
If this mtDNA background does have a deleterious effect, it would be expected that haplogroup J should result in a more pronounced respiratory chain defect, and thus influence the phenotype of LHON. Cybrid cell lines carrying the 11778GRA mutation and haplogroup J were shown to have a lower oxygen consumption and a longer doubling time compared with cell lines with the 11778GRA mutation alone. 20 However, a recently published study showed no difference in respiratory chain function between cybrid cell lines harbouring mtDNA from different haplogroups on the same 3460GRA  5  3  1  -1  --11778GRA  9  3  1  3  2  --14484TRC  1  --1  ---Controls  179  74 (41) 32 (18) 25 (14) 21 (12) 18 (10) 9 (5) % in brackets.
Electronic letternuclear genetic background. 19 In vivo magnetic resonance spectroscopy in patients harbouring the 11778GRA mutation also failed to detect any deleterious effect in brain and skeletal muscle from haplogroup J. 21 The influence of haplogroup J on the biochemical features of the 14484TRC mutation has not yet been determined. This result would be interesting in order to clarify the much stronger association of haplogroup J with 14484TRC compared with 11778GRA. However, these studies will require cautious interpretations, given that both in vitro and in vivo biochemical studies have produced conflicting results regarding the extent of respiratory chain dysfunction in LHON. There is currently no evidence that haplogroup J influences age of onset or final visual outcome in LHON, although this trend requires further confirmation in a larger LHON cohort. 22 Haplogroup J is one of nine European specific haplogroups, and therefore it would also be expected that LHON should be more common in populations of European extraction. This hypothesis will be difficult to test, given the paucity of data regarding the prevalence of LHON in different ethnic groups, and potential confounding factors such as a population bottleneck. 23 The analysis presented here also provides strong statistically based evidence that there is no association between haplogroup J and the 3460GRA mtDNA mutation. This is a most intriguing finding, given the strong haplogroup affiliation for the two other primary LHON mutations. However, the 3460GRA mutation seems to behave differently in a number of ways. Firstly, 3460GRA is the LHON mutation most consistently associated with a significant biochemical complex I defect; secondly, compared with the 14484TRC mutation, it is associated with a poorer visual outcome; and thirdly, it is associated with a less prominent gender bias. 24 This evidence suggests that 3460GRA is perhaps a ''stronger'' mutation-that is, less susceptible to the epistatic and epigenetic factors influencing the expression of the 14484TRC mutation and possibly the 11778GRA mutation.
Based on our meta-analysis of all published and unpublished datasets, there seems to be little doubt that the 14484TRC mutation, and to a lesser extent the 11778GRA mutation, are over-represented in haplogroup J, but several additional questions remain unanswered. What is the combination of polymorphisms within haplogroup J that increases the risk of disease expression? Unfortunately, there are insufficient published data available to carry out haplogroup J sub-cluster analysis and explore further the differences reported in sub-clusters J1 and J2. 10 Why should the 3460GRA mutation prove refractory to the mitochondrial genetic background? We have as yet no answer. Addressing these important issues will not only advance our understanding of LHON, but will also have broader relevance for other pathogenic mtDNA mutations.
